Wntresearch AB Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
03/05 | WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
29/02 | WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.69Cr 39Cr 307.7Cr |
---|---|---|---|---|---|
Net income 2022 | -3Cr -32Cr -250.24Cr | Net income 2023 | -3.2Cr -34Cr -266.92Cr | EV / Sales 2022 | - |
Net cash position 2022 | 99.18L 10Cr 83Cr | Net cash position 2023 | 2.69Cr 28Cr 224.25Cr | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.24
x | P/E ratio 2023 |
-0.87
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 15.12% |
Managers | Title | Age | Since |
---|---|---|---|
Per Norlén
CEO | Chief Executive Officer | 54 | 10/01 |
Founder | 68 | 24/07/24 | |
Anders Tidfors
DFI | Director of Finance/CFO | - | 11/20/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | 09/15/09 | |
Founder | 68 | 24/07/24 | |
Chairman | 62 | 01/22/01 |
1st Jan change | Capi. | |
---|---|---|
+11.91% | 12TCr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr |